Table 1. Baseline characteristics (N=120), cohort A.
| N (%) | |
|---|---|
| Median age, years (range) | 58.3 (29–73) |
| Male | 82 (68) |
| Performance status | |
| 0 | 24 (20) |
| 1 | 67 (56) |
| 2 | 28 (23) |
| 3 | 1 (1) |
| Previous therapy: | |
| Nephrectomy | 59 (49) |
| Number of disease sites | |
| 1 | 17 (14) |
| 2 | 35 (29) |
| 3 | 35 (29) |
| 4 or more | 33 (28) |
| Most common sites of disease | |
| Lymph node | 80 (67) |
| Lung/pleura | 74 (62) |
| Primary kidney tumor | 61 (51) |
| Liver | 36 (30) |
| Bone | 30 (25) |
| Local recurrence kidney bed | 18 (15) |
| Adrenal | 14 (12) |
| Other | 15 (13) |
| Histology | |
| Clear cell carcinoma | 111 (93) |
| Papillary | 4 (3) |
| Chromofobe | 2 (2) |
| Unclassified | 3 (3) |
| MSKCC prognostic criteria: a | |
| Favourable | 15 (13) |
| Intermediate | 65 (57) |
| Poor | 35 (30) |
a
Memorial Sloan Kettering Cancer Center (Motzer et al, 1999).